PCN33 COST-EFFECTIVENESS ANALYSIS OF SORAFENIB ASSOCIATED TO BEST SUPPORTIVE CARE (BSC) VERSUS BEST SUPPORTIVE CARE ALONE IN THE SECOND LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
2009
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI